|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Michael Ramroth||Chairman of the Management Board, CEO & CFO||1,21M||N/D||1961|
|Dr. Georg FloÃ||COO & Member of the Board of Management||1,05M||N/D||N/D|
|Dr. Monika Buttkereit||Head of Investor Relations||N/D||N/D||N/D|
|Dr. Christina Erb||Head of Corp. HR||N/D||N/D||N/D|
|Dr. Katrin BernÃ¶ster||Head of the Project Management Organisation||N/D||N/D||N/D|
|Mr. Peter Seith||Head of Quality Operations||N/D||N/D||N/D|
|Dr. JÃ¶rg SchÃ¼ttrumpf||Head of R&D||N/D||N/D||N/D|
|Dr. Wolfgang MÃ¶ller||Head of Devel. - Plasma Protein||N/D||N/D||N/D|
|Dr. Hermann Keuper||Sr. VP of Manufacturing||N/D||N/D||N/D|
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; Anti-SARS-CoV-2 hyperimmunoglobulin for COVID-19 treatment; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.
L'ISS Governance QualityScore di Biotest Aktiengesellschaft al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.